secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verastem, Inc. (VSTM)
CIK:        0001526119
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0001104659-25-052220
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verastem reports 83% ORR for avutometinib+defactinib in front-line metastatic PDAC
--------------------------------------------------------------------------------

- Dose level 1 (RP2D) achieved 83% ORR (10/12 partial responses) in RAMP 205 trial of frontline metastatic pancreatic cancer.
- Across all 5 dose cohorts, 92% (48/52) of evaluable patients showed tumor reduction.
- Company plans to start registrational Phase 3 trial in front-line metastatic PDAC in 2026.
- No new safety signals; adverse events consistent with previously reported profile.
- R&D webcast on June 2, 2025 to discuss RAMP 205 data and VS-7375 KRAS G12D inhibitor data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925052220/0001104659-25-052220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1526119/000110465925052220/tm2516049d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-052220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer